Advertisements

Folsäure-Hevert

Quick links to important sections

Folsäure-Hevert

Advertisements
Advertisements

Method of action: Antianemic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Folsäure-Hevert

What is Folsäure-Hevert?

Folsäure-Hevert is a vitamin preparation containing folic acid, a synthetic form of folate. Folate is a water-soluble B-vitamin (vitamin B9) that is essential for numerous metabolic processes within the human body.

Role of Folic Acid

Folic acid plays a critical role in cell division and the formation of new cells. It is a fundamental component in the synthesis of DNA and RNA, the genetic building blocks of the body. Furthermore, it is involved in the maturation of red and white blood cells in the bone marrow.

Application and Purpose

This preparation is primarily used to address folate deficiency states that cannot be corrected through dietary changes alone. A deficiency in folic acid can lead to various physiological issues, most notably forms of anemia characterized by abnormally large red blood cells.

By providing a concentrated source of the vitamin, Folsäure-Hevert helps to restore adequate folate levels, supporting healthy blood formation and cellular growth. It is often utilized in situations where there is an increased physiological demand for the vitamin or when absorption from food sources is insufficient.

Advertisements

What side effects are possible with Folsäure-Hevert?

Possible side effects and safety information

The safety profile of Folic Acid, the active ingredient in Folsäure-Hevert, is characterized by a low incidence of direct adverse reactions and one critical safety constraint related to pre-existing conditions.

Officially Documented Adverse Reactions

Adverse events documented in official regulatory sources are generally uncommon and primarily classified under the Immune System Disorders and Skin and Subcutaneous Tissue Disorders System-Organ Classes.

Adverse Reaction Category Frequency Classification
Skin Reactions (e.g., rash, pruritus, erythema) Rare
Gastrointestinal Issues (e.g., nausea, flatulence) Not Classified (Reported)
Anaphylactic Reaction/Shock (Systemic allergic response) Very Rare / Frequency Not Known

An Anaphylactic Reaction represents the most serious adverse reaction documented, though its occurrence is considered very rare.

Critical Safety Constraints and Limitations

The most significant safety limitation is strictly related to administration in individuals with an undiagnosed Vitamin B12 deficiency. Folic Acid must not be used alone to treat megaloblastic anemia until Vitamin B12 deficiency has been ruled out.

This constraint exists because Folic Acid therapy can mask the hematological symptoms of B12 deficiency (improving the blood picture) while failing to prevent the associated and potentially irreversible neurological damage from progressing. Therefore, Folic Acid administration in this context is considered improper therapy by regulatory bodies.

Official labels also note that Folic Acid is contraindicated in cases of known hypersensitivity to the active substance or excipients.

Advertisements

Overdose and Emergency Response

The regulatory overdose profile for Folsäure-Hevert (Folic Acid) reflects the substance’s wide margin of safety and water-soluble nature, meaning acute toxicity is generally rare.

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Gastrointestinal disturbances, including flatulence, nausea, abdominal distention, and a bitter taste, are reported primarily with chronic, high-dose ingestion.
Physiological systems affected Manifestations affect the gastrointestinal system and the Central Nervous System, presenting as altered sleep patterns, overactivity, and irritability.
Population-specific overdose notes High-dose exposure is associated with an increased incidence of seizures in epileptic patients taking certain anticonvulsants.
When immediate medical help is required Immediate medical attention must be sought for any suspected overdose or the manifestation of severe, life-threatening symptoms, such as collapse, trouble breathing, or signs of a severe allergic reaction, including swelling of the face or throat.

Overdose Classifications

Property Official Regulatory Statement
Severity classification Generally categorized as low acute systemic toxicity; life-threatening outcomes are rare hypersensitivity reactions (e.g., anaphylaxis).
Overdose-context constraints No specific pharmacological antidote is known. The critical long-term risk of high-dose exposure is the masking of Vitamin B12 deficiency (Pernicious Anemia), which allows neurological damage to progress untreated.

Resulting Overdose Structure

Official overdose statements:

  • Overdose symptoms are typically non-specific, mild, and primarily affect the digestive and nervous systems.
  • Management is limited to symptomatic and supportive treatment, as no specific antidote is available.
  • Regulators require that emergency services be contacted immediately if symptoms of a severe allergic reaction or other acute, life-threatening events occur.
  • High-dose exposure is associated with the critical diagnostic constraint of masking the signs of an underlying Vitamin B12 deficiency.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by detailing non-specific, primarily mild manifestations that occur at high exposures. They mandate seeking urgent medical help in cases involving rare but severe outcomes like allergic reactions or seizures, or when any life-threatening sign is observed. This information structures the required emergency actions around supportive care and the critical need to assess for the long-term risk of pernicious anemia masking associated with high chronic dosing.

Advertisements

Therapeutic Uses of Folsäure-Hevert

What Folsäure-Hevert Treats: Main Uses and Benefits

Folsäure-Hevert is applied across domains where additional symptomatic support is needed. It is used across domains where short-term symptom management is appropriate, particularly in conditions marked by increased physiological stress. It is commonly used to help with conditions characterized by periods of heightened symptoms.

The therapeutic use is relevant across several core domains: in addressing fatigue and systemic symptoms related to deficiency, in providing preventative support for fetal development (especially concerning Neural Tube Defects), and in assisting with management of elevated homocysteine levels linked to vascular concerns.

Easing Deficiency Symptoms and Supporting Comfort

This medicine is applied across domains where additional symptomatic support is needed for the cluster of symptoms related to systemic imbalance (such as fatigue, weakness, and pallor) caused by a deficiency in folic acid. It is relevant for managing symptoms that interfere with daily comfort. The medication provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supports general well-being during symptomatic phases related to nutritional deficiency.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Folsäure-Hevert — official regulatory information

Eligibility Scope Detail from Regulatory Documents
Populations for whom use is allowed (as stated in label) Adults, Adolescents, and Children (6 years and older) are generally eligible for treatment. Pregnant and Lactating women are permitted to use the medicine under regulatory guidance.
Populations for whom use is contraindicated Patients with untreated cobalamin (Vitamin B12) deficiency or undiagnosed megaloblastic anaemia must not use this medicine. It is also contraindicated for individuals with known hypersensitivity to Folic Acid.
Age-related eligibility rules Children under six years are generally restricted from standard high-dose formulations, requiring specific low-dose guidance. Elderly patients may require cobalamin testing prior to long-term therapy.
Condition-specific eligibility rules Use is prohibited in patients with malignant disease unless megaloblastic anaemia is specifically identified as an important complication. It is also contraindicated due to the lactose excipient in patients with hereditary problems such as Lapp lactase deficiency.
Pregnancy and lactation eligibility status Permitted in both pregnancy and lactation, with no known hazards documented.

Connection to the overall eligibility profile

The official eligibility profile is strictly defined by the mandatory exclusion of individuals with undiagnosed or untreated Vitamin B12 deficiency, which Folic Acid can mask. Use is permitted for most other age groups and physiological states but is subject to explicit restrictions related to underlying malignancy or specific excipient intolerance as documented in the product labeling.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Folsäure-Hevert (Folic Acid) is based on official government regulatory documents and involves several medicinal product classes and non-medicinal substances.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Folic Acid is documented to interact with several drugs by altering their plasma levels or by mutual antagonism of effects.

Interacting Substance/Class Regulatory Finding
Anticonvulsants (e.g., Phenytoin, Phenobarbital) Folic Acid may decrease the serum levels, potentially reducing their effectiveness.
Folic Acid Antagonists (e.g., Methotrexate, Trimethoprim) The effects of Folic Acid and these antagonists may be mutually inhibited.
Chloramphenicol (Antibiotic) Can hinder the blood cell formation response to Folic Acid treatment.
Fluorouracil (Cytostatic) High doses of Folic Acid may increase toxicity, specifically severe diarrhoea.

Restrictions and Timing Requirements

Specific restrictions and time-separation rules exist to manage absorption interference and toxicity risks.

  • Absorption Interference: Substances like antacids (containing aluminium or magnesium) and Cholestyramine may reduce Folic Acid absorption. Antacids require administration at least two hours after Folic Acid, and Cholestyramine must be separated by 1 hour or 4 to 6 hours.
  • Contraindicated State: Folic Acid is formally contraindicated in the context of untreated Vitamin B12 deficiency to prevent the masking of hematological symptoms while irreversible neurological damage progresses.
  • Non-Medicinal Interactions: Alcohol (ethanol) may increase Folic Acid elimination. Folic Acid may reduce the intestinal absorption of co-administered Zinc.
Advertisements

Mechanism of Action

Folsäure-Hevert provides Folic Acid, which acts as an essential precursor in core metabolic pathways. The mechanism operates by furnishing essential metabolic precursors required for cellular processes.


C1 Metabolism and DNA Synthesis Cascade

The synthetic Folic Acid precursor is first reduced by the enzyme dihydrofolate reductase (DHFR) into its active co-factors, primarily tetrahydrofolate (THF). THF derivatives are critical for one-carbon ( C1) metabolism, where they donate carbon units essential for the de novo synthesis of purine bases and deoxythymidine monophosphate (dTMP), the building blocks of DNA. This mechanism overcomes impaired DNA replication in rapidly dividing cells, supporting the proper division and maturation of cells within the haemopoietic system.


Modulation of Homocysteine and B12 Interdependence

Active folate (5-MTHF) is required to facilitate the remethylation of homocysteine back into methionine, a reaction catalyzed by methionine synthase that is strictly dependent on Vitamin B12. This mechanistic domain facilitates the remethylation of homocysteine, influencing systemic concentrations of this amino acid and its downstream effects on vascular tissues. The effectiveness of the folate mechanism is constrained by a severe B12 deficit, which functionally traps the folate cofactor, demonstrating a critical interdependency within the C1 pathway.

Advertisements

Dosage and Administration Information

How to Use Folsäure-Hevert: Official Administration Guidelines

Folsäure-Hevert's usage focuses on specific routes, standardized doses, and a phased treatment approach. The standard administration is typically once daily for both therapeutic and maintenance purposes.


Administration Scope

Feature Official Instruction / Pattern
Route of administration Primarily oral (tablet). Also approved for parenteral administration (Intravenous, Intramuscular, or Subcutaneous) using the injection solution when oral absorption is impaired.
Dosing schedule Therapeutic Dosing: Up to 1 mg once daily or 5 mg once daily to correct deficiency, typically for a short duration. Maintenance Dosing: Lower, long-term daily dose (e.g., 0.4 mg to 0.8 mg) once blood values normalize.
Timing in relation to meals The oral tablet can generally be taken with or without food, independent of meal times.
Preparation requirements The oral tablet requires no special preparation. The parenteral solution must be administered by qualified healthcare personnel in a controlled setting.

Procedural Structure and Course Duration

Treatment with Folic Acid follows a structured course. Initially, a higher therapeutic dose is administered once daily until the patient's blood picture returns to normal, marking the end of the short-term course. Following this, the regimen transitions to a lower, once-daily maintenance dose for long-term support. Doses exceeding 1 mg daily generally do not enhance the hematological effect when deficiency is not severe. Dosage adjustments are defined for specific populations, such as higher maintenance doses required for pregnant and lactating women.

Advertisements

Recent Clinical Evidence

Folsäure-Hevert: Recent Clinical Evidence

Folsäure-Hevert contains folic acid, the synthetic form of folate (Vitamin B9). Research evidence predominantly focuses on the role of folic acid supplementation in maintaining adequate folate status for essential metabolic processes, particularly those involving cell division and the metabolism of the amino acid homocysteine.


Prevention of Neural Tube Defects (NTDs)

The most significant and consistently supported clinical evidence for folic acid relates to the primary prevention of Neural Tube Defects (NTDs), which are serious birth defects of the brain and spine. Multiple randomized controlled trials (RCTs) and subsequent meta-analyses have established a protective effect of folic acid supplementation when taken in the periconceptional period (before and during early pregnancy).

  • Key Finding: Studies consistently show that folic acid supplementation, typically at a dose of 400 micrograms (0.4 mg) daily, substantially lowers the risk of NTDs in the developing fetus. The timing of supplementation, ideally starting at least one month before conception and continuing through the first 12 weeks of pregnancy, is considered crucial for this preventative effect.

Other Areas of Research

Clinical research has also investigated folic acid in other contexts, primarily due to its role in homocysteine metabolism.

Research Focus Summary of Findings
Homocysteine Levels Supplementation is strongly associated with lowering plasma homocysteine levels, an effect observed in multiple studies.
Cardiovascular Health Research, including systematic reviews of RCTs, suggests that while folic acid supplementation may not significantly affect the risk of major cardiovascular events or heart attacks, it has been linked to a decreased risk of stroke in some populations.
Folate Deficiency Folic acid is studied for correcting megaloblastic anemia caused by folate deficiency, with evidence supporting its use to restore normal blood counts. However, its use requires careful assessment of concurrent Vitamin B12 status.

Overall, the consensus among authoritative medical bodies underscores the importance of folic acid for public health, particularly for individuals who are planning or capable of pregnancy, to ensure optimal folate status during critical periods of fetal development.

Key Studies & References

  1. Folic Acid Supplementation for the Prevention of Neural Tube Defects: An Updated Evidence Report and Systematic Review - USPSTF
  2. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials
  3. Cobalamin (vitamin B12) and Folate Deficiency - British Columbia Medical Guidelines
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Folsäure-Hevert (FAQ)


Q: Is there a difference in how vegetarians or vegans use Folsäure-Hevert?

A: Folic acid alone is considered improper therapy for megaloblastic anemias caused by a Vitamin B12 deficiency. Official regulatory documents indicate that B12 testing should be considered or is necessary before beginning long-term folate therapy, especially for individuals at risk of B12 deficiency, such as those following strict vegetarian diets.


Q: Could Folsäure-Hevert affect the results of blood tests?

A: Regulatory documents mention that certain drug interactions may interfere with laboratory accuracy. For instance, if a patient is taking specific antibiotics, such as tetracycline, this may cause false low serum and red cell folate levels, which could impact the accuracy of folate-specific blood tests.


Q: Why do some people say they feel more energetic after starting Folsäure-Hevert?

A: The purpose of Folsäure-Hevert is to correct deficiencies that cause megaloblastic anemia. Since a lack of folate is linked to symptoms like fatigue and weakness, correction of this deficiency supports the body's proper blood cell formation, which is the mechanism intended to address the underlying cause of fatigue and weakness.


Q: Does Folsäure-Hevert contain lactose, gluten, or sugar?

A: According to official product information for Folic Acid tablets, the preparation may contain lactose monohydrate as an inactive ingredient. The presence or absence of excipients like gluten or refined sugar (sucrose/dextrose) is typically detailed in the full product labeling.


Q: Are there long-term studies available on the use of Folsäure-Hevert?

A: Folic acid is often prescribed for long-term maintenance in certain chronic deficiency states. However, regulatory documents for some Folic Acid preparations note that specific long-term studies to evaluate carcinogenic potential (potential to cause cancer) in animals have not been conducted.


Q: How does the body absorb the folic acid in Folsäure-Hevert compared to folate from food?

A: Studies and official information indicate that the synthetic Folic Acid found in the tablet is highly bioavailable, meaning it is absorbed very efficiently by the body. Naturally occurring folates found in food are known to exhibit incomplete and more variable bioavailability when compared to supplemental folic acid.


Q: Can Folsäure-Hevert be used in combination with other B-vitamins?

A: Folic acid is frequently included in multivitamin supplements that contain other B-vitamins. However, the critical regulatory warning indicates that high doses of folic acid should not be administered alone if a Vitamin B12 deficiency is present or has not been assessed.


Q: Does Folsäure-Hevert interact with common pain relievers like ibuprofen?

A: Official health guidance generally suggests that Folic Acid can be used alongside common non-NSAID painkillers. Information from authoritative sources indicates that potential interactions with other necessary medications should be reviewed with a health professional, particularly if the patient is also using methotrexate, as NSAIDs are known to interact with that drug.


Q: How long does it typically take to notice the effects of Folsäure-Hevert?

A: Pharmacological data from regulatory documents indicate that the folic acid in the tablet is absorbed quickly. The substance appears in the bloodstream approximately 15 to 30 minutes after an oral dose is taken, with peak plasma levels generally reached within one hour.


Q: If I miss a dose of Folsäure-Hevert, what is the general recommendation?

A: If a dose is missed, regulatory patient instructions indicate that it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. Patients are advised not to take two doses together to make up for a forgotten one.


Q: What happens if I accidentally take more Folsäure-Hevert than described in the labeling?

A: Folic acid is generally considered to be relatively nontoxic, and taking slightly more than the labeled amount is unlikely to cause serious harm. Documented high-dose side effects may include a bitter taste, nausea, or loose stools, and if there are concerns, contact with a healthcare professional is the standard procedure described in patient guidance.


Q: Is it possible to have too much folic acid when using Folsäure-Hevert?

A: Folic acid is considered relatively nontoxic, but taking high doses is associated with a key safety constraint. High doses may mask the symptoms of an undiagnosed Vitamin B12 deficiency, which can allow potentially irreversible neurological damage to progress unnoticed. High intake has also been associated with reported gastrointestinal issues.


Q: Where can I find official information or clinical trials about Folsäure-Hevert?

A: Authoritative information about the active ingredient, Folic Acid, can be found on government-run websites like DailyMed (FDA) or MedlinePlus (NIH). Information on clinical trials involving folic acid is also available through public registers like ClinicalTrials.gov.


Q: What should I generally do if I experience an unexpected side effect from Folsäure-Hevert?

A: If a patient experiences any unexpected or concerning side effects, standard health guidance indicates that contact with a doctor or pharmacist is necessary for assessment. All regulatory systems encourage patients to report suspected adverse reactions to their national regulatory body for monitoring.

Advertisements

How should Folsäure-Hevert be stored and disposed of?

How to Store and Dispose of Folsäure-Hevert?

Folsäure-Hevert (Folic Acid) tablets must be stored according to official regulatory requirements to ensure product stability and safety.

Mandatory Storage Conditions

The medicine must be stored in the original package to protect from light and moisture. The required storage temperature must not exceed 25 C (store below 25 C). The product must be kept out of the sight and reach of children at all times. Do not use Folsäure-Hevert after the printed expiry date.

Disposal Requirements

Official instructions prohibit the disposal of unused or expired Folsäure-Hevert through wastewater or household waste. To discard the product safely and help protect the environment, users must ask a pharmacist for guidance on proper disposal, following all applicable local requirements for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folsäure-Hevert found in:

A-Z Index: